This is a summary of the European public assessment report (EPAR) for Idelvion. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Idelvion. For practical information about using Idelvion, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Therapeutic Area (MeSH)
N/AATC Code
B02BD04
ATC Item
coagulation factor IX
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| albutrepenonacog alfa | N/A | Albutrepenonacog alfa |
EMA Name
Idelvion
Medicine Name
Idelvion
Aliases
N/ANo risk management plan link.
